
    
      This is an open-label, randomized, multicenter, parallel group, concurrent, controlled study
      using a sequential adaptive design to evaluate the efficacy and safety of RESP301 plus SOC
      versus SOC alone in hospitalized patients with COVID-19 (World Health Organization [WHO]
      ordinal scale level 3 or 4).

      Approximately 300 participants will be enrolled and randomized 2:1 to the Investigational arm
      or the Control arm. The study will be divided into the following periods: Screening period:
      (up to 2 days), Intervention (up to 10 days), follow-up (Day 14 and Day 28).
    
  